Indian inhaler market is anticipated to grow at a substantial rate of 7.4% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the country. The Indian inhaler market is segmented on the basis of device, type, application, and end-user. On the basis of device, the market is sub-segmented into metered dosed inhaler, dry powdered inhaler, and nebulizer. The dry powder inhaler is estimated to have largest market share in the Indian inhaler market due to providing easy inhalation solution. Based on the type, preventive, reliever, and long acting bronchodilators inhaler are analyzed. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
To Request a Sample of our Report on Indian Inhaler Market: https://www.omrglobal.com/request-sample/indian-inhaler-market
Cipla is one of the major companies working in the inhaler market. The company offers products in the field of asthma, COPD, Allergic Rhinitis (AR), Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF). In May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access of life-changing medicines in India.
(Get 15% Discount on Buying this Report)
A full Report of Indian Inhaler Market is Available at: https://www.omrglobal.com/industry-reports/indian-inhaler-market
Indian Inhaler Market Segmentation
By Device
· Metered Dose Inhaler
· Dry Powder Inhaler
· Nebulizer
By Type
· Preventive Inhaler
· Reliever Inhaler
· Long Acting Bronchodilators Inhaler
· By Application
· Asthma
· Chronic Obstructive Pulmonary Disease (COPD)
By End-User
· Homecare
· Hospitals and Clinics
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
